Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyaluronidase for Sclerodactyly in Systemic Sclerosis
NCT07697274Phase 1Not yet recruiting
- Sponsor
- Medical University of South Carolina
- Start
- Nov 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hyaluronidase in systemic sclerosis (SSc) and sclerodactyly, sponsored by Medical University of South Carolina. Primary endpoints: Feasibility Assessment at 28 weeks and Evaluate Safety at 32 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
hyaluronidase
03
Conditions
systemic sclerosis (SSc)sclerodactyly
Beyond the preview
Go deeper on NCT07697274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07697274.